About Us

Home

About Us

Product R&D

Left Ventricular Assist Device

Patient Support

Treatment Process Recovery Story Clinical Network

News & Updates

Join Us

Company Introduction

EVAHEART Medical was established in 2014, focusing on the research, development, and manufacturing of innovative medical devices in the fields of heart failure and pan-vascular diseases. The company has built an integrated system encompassing R&D, production, and total system solutions.

The company's core products include a dual-indication Left Ventricular Assist Device for both Destination Therapy and Bridge-To-Transplant, as well as an Extra Ventricular Assist Device

. In Chongqing Liangjiang New Area, the company has established China's first medical device industrial park dedicated to heart failure treatment, achieving full self-sufficiency and control over the artificial heart industry chain.

<br />
<b>Notice</b>: Undefined index: classname in <b>/www/wwwroot/evaheart.com/en/about.php</b> on line <b>97</b><br />

Vision and Mission

Provide innovative Heart Failure and Pan-vascular solutions for global patients and healthcare professionals.

Values

Customer Focus

Innovation Driven

Integrity and Ownership

Milestone

2025

Next-generation lightweight compact controller received regulatory approval for market launch

2024

EVAHEART Technology Park completed

2023

EVAHEART Medical completed Series A capital increase

2023

EVA-Pulsar™ Launched

2021

VIVO CAPITAL completed majority acquisition of EVAHEART Medical

2020

Awarded "2019 China Major Medical Advances"

2019

EVAHEART Left Ventricular Assist System received regulatory approval for market launch

2014

EVAHEART officially established

2025

Next-generation lightweight compact controller received regulatory approval for market launch

EVAHEART achieved full-chain iterative development of LVAD products

2024

EVAHEART Technology Park completed

The EVAHEART Technology Park is an industrial park themed around the treatment of heart failure and pan-vascular diseases

2023

EVAHEART Medical completed Series A capital increase

New shareholders including Sinovac, Taiping Insurance, China Reinsurance, and Yonghua Capital joined the company to further build a platform for heart failure and pan-vascular disease treatment

2023

EVA-Pulsar™ Launched

The next-generation LVAD EVA-Pulsar™ received regulatory approval for market launch in China

2021

VIVO CAPITAL completed majority acquisition of EVAHEART Medical

VIVO CAPITAL, the global healthcare investment fund with the largest assets under management, completed the majority acquisition of EVAHEART Medical.

2020

Awarded "2019 China Major Medical Advances"

2019

EVAHEART Left Ventricular Assist System received regulatory approval for market launch

EVAHEART Left Ventricular Assist Device received regulatory approval for market launch (CMDR No.20193120603), becoming China's first approved Left Ventricular Assist Device product, "marking the entry of China's severe heart failure treatment into the LVAD era"

2014

EVAHEART officially established

Core team members have long-term deep expertise in the implantable medical device field, integrating precision engineering and core cardiovascular technologies

Possessing complete end-to-end industry chain experience from product definition, R&D translation, scaled production, market access, to commercial rollout

Honors and Qualifications

EVAHEART strictly adheres to medical device regulations and quality management system requirements, having established a compliance management system covering the full lifecycle of R&D, manufacturing, and clinical translation, and having obtained multiple medical device production and quality system certifications.